File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Use of glecaprevir/pibrentasvir in patients with chronic hepatitis C virus infection and severe renal impairment

TitleUse of glecaprevir/pibrentasvir in patients with chronic hepatitis C virus infection and severe renal impairment
Authors
KeywordsGlecaprevir and pibrentasvir
Hepatitis C
Renal insufficiency
Issue Date2020
PublisherKorean Association for the Study of the Liver. The Journal's web site is located at http://www.e-cmh.org
Citation
Clinical and Molecular Hepatology, 2020, v. 26 n. 4, p. 554-561 How to Cite?
AbstractBackground/Aims: Data on treatment efficacy and safety of glecaprevir/pibrentasvir (GLE/PIB) for chronic hepatitis C virus (HCV) infection in Asian patients with severe renal impairment are limited. This study aimed to study the treatment and side effects of GLE/PIB in these patients infected with non-1 genotype (GT) HCV. Methods: We prospectively recruited patients with Child’s A cirrhosis and eGFR <30 mL/min/1.73 m2 in Hong Kong and Taiwan during 2017–2018 to receive GLE/PIB treatment. Results: Twenty-one patients (GT2, n=7; GT3, n=6; and GT6, n=8) received GLE/PIB for 11.2±1.8 weeks. All except one were treatment-naïve. GLE/PIB was initiated in 16 patients while on dialysis (seven on peritoneal dialysis [PD] and nine on hemodialysis) and in five patients before dialysis. One patient died of PD-related peritonitis during treatment and two were lost to follow up. The SVR12 rate in the remaining 18 patients was 100%. All patients achieved undetectable levels at 4-, 12-, 24- and 48-week after treatment. Patients with deranged alanine aminotransferase showed normalization after 4 weeks and the response was sustained for 48 weeks. No significant adverse event was observed. Conclusions: GLE/PIB treatment was associated with high efficacy and tolerability in HCV-infected patients with severe renal impairment. Go to : Goto
Persistent Identifierhttp://hdl.handle.net/10722/291179
ISSN
2019 Impact Factor: 3.987
2015 SCImago Journal Rankings: 0.899
PubMed Central ID
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorYap, DYH-
dc.contributor.authorLiu, KSH-
dc.contributor.authorHsu, YC-
dc.contributor.authorWong, GLH-
dc.contributor.authorTsai, MC-
dc.contributor.authorChen, CH-
dc.contributor.authorHsu, CS-
dc.contributor.authorHui, YT-
dc.contributor.authorLi, MKK-
dc.contributor.authorLiu, CH-
dc.contributor.authorKan, YM-
dc.contributor.authorYu, ML-
dc.contributor.authorYuen, MF-
dc.date.accessioned2020-11-07T13:53:20Z-
dc.date.available2020-11-07T13:53:20Z-
dc.date.issued2020-
dc.identifier.citationClinical and Molecular Hepatology, 2020, v. 26 n. 4, p. 554-561-
dc.identifier.issn2287-2728-
dc.identifier.urihttp://hdl.handle.net/10722/291179-
dc.description.abstractBackground/Aims: Data on treatment efficacy and safety of glecaprevir/pibrentasvir (GLE/PIB) for chronic hepatitis C virus (HCV) infection in Asian patients with severe renal impairment are limited. This study aimed to study the treatment and side effects of GLE/PIB in these patients infected with non-1 genotype (GT) HCV. Methods: We prospectively recruited patients with Child’s A cirrhosis and eGFR <30 mL/min/1.73 m2 in Hong Kong and Taiwan during 2017–2018 to receive GLE/PIB treatment. Results: Twenty-one patients (GT2, n=7; GT3, n=6; and GT6, n=8) received GLE/PIB for 11.2±1.8 weeks. All except one were treatment-naïve. GLE/PIB was initiated in 16 patients while on dialysis (seven on peritoneal dialysis [PD] and nine on hemodialysis) and in five patients before dialysis. One patient died of PD-related peritonitis during treatment and two were lost to follow up. The SVR12 rate in the remaining 18 patients was 100%. All patients achieved undetectable levels at 4-, 12-, 24- and 48-week after treatment. Patients with deranged alanine aminotransferase showed normalization after 4 weeks and the response was sustained for 48 weeks. No significant adverse event was observed. Conclusions: GLE/PIB treatment was associated with high efficacy and tolerability in HCV-infected patients with severe renal impairment. Go to : Goto-
dc.languageeng-
dc.publisherKorean Association for the Study of the Liver. The Journal's web site is located at http://www.e-cmh.org-
dc.relation.ispartofClinical and Molecular Hepatology-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.subjectGlecaprevir and pibrentasvir-
dc.subjectHepatitis C-
dc.subjectRenal insufficiency-
dc.titleUse of glecaprevir/pibrentasvir in patients with chronic hepatitis C virus infection and severe renal impairment-
dc.typeArticle-
dc.identifier.emailYap, DYH: desmondy@hku.hk-
dc.identifier.emailLiu, KSH: drkliu@hku.hk-
dc.identifier.emailYuen, MF: mfyuen@hku.hk-
dc.identifier.authorityYap, DYH=rp01607-
dc.identifier.authorityYuen, MF=rp00479-
dc.description.naturepublished_or_final_version-
dc.identifier.doi10.3350/cmh.2020.0058-
dc.identifier.pmid32854457-
dc.identifier.pmcidPMC7641551-
dc.identifier.scopuseid_2-s2.0-85092799720-
dc.identifier.hkuros318656-
dc.identifier.volume26-
dc.identifier.issue4-
dc.identifier.spage554-
dc.identifier.epage561-
dc.identifier.isiWOS:000580510600017-
dc.publisher.placeRepublic of Korea-
dc.identifier.issnl2287-2728-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats